[ad_1]
Data published in Neuropharmacology stand by In this case, the therapeutic effect of divaleric acid important Dyskinesia
giveNiva, Switzerland, May 17, 202 pcs1 piece – Addex Therapeutics (Nasdaq:ADXN) Is a clinical-stage pharmaceutical company that pioneered drug discovery and development based on allosteric regulation. It announced today that in two fully validated models of dystonia, double glia can save the long-term damage to synaptic plasticity. effect. The data has been published in the magazine, NeuropharmacologyThe research team led by Dr. Antonio Pisani of the Department of Brain and Behavioral Sciences of the University of Pavia in “Saving the long-term depression of the striatum through chronic mGlu5 receptor negative allosteric modulation in different models of dystonia” and Pavia, Italy The Mondino Foundation.
“Due to the current lack of effective treatment options, there is an urgent need to identify targets for dystonia and design effective treatments. We evaluated the use of dipyrrolidone on mGlu5 receptors in two etiologically different dystonia models. Inhibition studies have shown that this target has now been validated as a promising method for the treatment of dystonia,” said Dr. Pisani. “In addition, the data shows that there are common mechanisms and signaling pathways that are impaired in different forms of dystonia, highlighting the potential of divalproic acid as a new therapeutic approach for the treatment of dystonia. This hypothesis is clinically carried out. Inspection is necessary.”
In these studies, the researchers showed that long-term use of dual flavor agents can rescue the damaged cortical orifice synapses in DYT1 mice and GNAL rats (two different models). Long-term synaptic inhibition (LTD) (a type) Synaptic plasticity) loss. Dystonia.
“The discovery that long-term administration of dual flavors can restore the plasticity of the striatum in a rodent model of multiple dystonia is a very important discovery. This discovery further strengthens the view that the method is effective in terms of regulation and muscle tone. Disorder-related defects may have great utility and further support the rationale for the development of this theory. Compound drugs can treat dystonia, including blepharospasm,” said Robert Lütjens, head of discovery biology at Addex. “Digraglurant is about to start a pivotal Phase 2b/3 clinical trial for the treatment of dyskinesias related to Parkinson’s disease, and will conduct a Phase 2 study in patients with blepharospasm this quarter.”
Addex is developing a sustained-release formulation of dual flavor agents for the treatment of blepharospasm. Dystonia is a form of dystonia characterized by involuntary muscle contraction and spasm of the eyelid muscles, resulting in continuous eyelid closure. This can lead to severe visual impairment or functional blindness. It is planned to start a placebo-controlled Phase 2 clinical trial of double globin in patients with blepharospasm in the second quarter of 2021. After regulatory approval, Addex believes that double globin therapeutics can provide innovative and differentiated treatments for many types of dystonia, and provide huge business opportunities.
About Addex Therapeutics:
Addex Therapeutics It is a clinical stage pharmaceutical company dedicated to the development and commercialization of new oral small molecule drugs (called allosteric modulators for neurological diseases). Allosteric modulators offer some potential advantages over conventional non-allosteric molecules, and can provide improved treatments for conventional “normal” small molecules or biopharmaceuticals. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s main product candidate, divalproex (mGlu5 negative allosteric modulator or NAM), is preparing for a key registration clinical trial for levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease in the second quarter of 2021. Type of dystonia), clinical trials are expected to start in the second quarter of 2021. The third clinical project ADX71149 (mGlu2-positive allosteric modulator or PAM), the third clinical project jointly developed by Addex and Janssen Pharmaceuticals, Inc., has entered the stage. 221 In the second quarter of 2021, a proof-of-concept clinical trial for epilepsy treatment. Addex’s GABAB PAM program has been licensed by Indivior PLC, a company focused on the development of addiction treatments. Preclinical plans include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive impairment, mGlu4 PAM for Parkinson’s disease, and mGlu3 PAM for neurodegenerative diseases. Addex’s shares are listed on the SIX Swiss Exchange, and the American Depositary Shares (ADS) representing its shares are listed on the NASDAQ Capital Market with the stock symbol on each exchange. “ADXN” transaction.
Press contact:
Forward-looking statement:
This press release contains forward-looking statements as defined in the revised “Private Securities Litigation Reform Act of 1995”, including the expected launch and progress of clinical trials and preclinical research, and future financing activities. “May”, “will”, “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “plan”, “believe”, “estimate”, “forecast”, etc. The words “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a variety of risks, uncertainties and important factors that may cause actual events or results to differ Any forward-looking statement or implied behavior makes a material difference. The forward-looking statements contained in this press release include, but are not limited to, uncertainties related to market conditions. These and other risks and uncertainties are described in the company’s annual report on Form 20-F submitted to the SEC on March 11, 2021, as well as market conditions and regulatory reviews.
Any forward-looking statements contained in this press release represent only the views of Addex Therapeutics as of the date of this article and should not be construed as representing its views on any subsequent date. Except as required by law, Addex Therapeutics expressly disclaims any obligation to update any forward-looking statements.
[ad_2]
Source link
